Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Cash from Investing Activities (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Cash from Investing Activities for 6 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 182.55% year-over-year to $9.7 million, compared with a TTM value of $13.3 million through Dec 2025, down 62.54%, and an annual FY2025 reading of $13.3 million, down 62.54% over the prior year.
  • Cash from Investing Activities was $9.7 million for Q4 2025 at Treace Medical Concepts, up from $8.7 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $22.4 million in Q2 2024 and bottomed at -$80.5 million in Q1 2023.
  • Average Cash from Investing Activities over 5 years is -$5.6 million, with a median of -$785000.0 recorded in 2021.
  • The sharpest move saw Cash from Investing Activities crashed 7012.44% in 2022, then surged 315.23% in 2024.
  • Year by year, Cash from Investing Activities stood at -$900000.0 in 2021, then plummeted by 7012.44% to -$64.0 million in 2022, then soared by 107.82% to $5.0 million in 2023, then tumbled by 31.68% to $3.4 million in 2024, then surged by 182.55% to $9.7 million in 2025.
  • Business Quant data shows Cash from Investing Activities for TMCI at $9.7 million in Q4 2025, $8.7 million in Q3 2025, and -$3.3 million in Q2 2025.